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Running title : G protein activation by monomeric and dimeric GPCRs
 
Accumulating evidence indicates that G 
protein-coupled receptors can assemble as 
dimers/oligomers but the role of this 
phenomenon in G protein coupling and 
signaling is not clear so far. We have used 
the purified leukotriene B4 receptor BLT2 
as a model to investigate the capacity of 
receptor monomers and dimers to activate 
the adenylyl cyclase inhibitory Gi2 protein. 
For this, we overexpressed the recombinant 
receptor as inclusion bodies in the 
prokaryotic system Escherichia coli, using a 
human α5 integrin as a fusion partner. This 
strategy allowed the BLT2 as well as several 
other G protein-coupled receptors from 
different families to be produced and 
purified in large amounts. The BLT2 
receptor was then successfully refolded to its 
native state, as measured by high-affinity 
LTB4 binding in the presence of the purified 
G protein Gα i2. The receptor dimer, in 
which the two protomers displayed a well-
defined parallel orientation as assessed by 
fluorescence resonance energy transfer, was 
then separated from the monomer. Using 
two methods of receptor-catalyzed GTPγS 
binding assay, we clearly demonstrated that 
monomeric BLT2 stimulates the purified 
Gα i2β1γ2 protein more efficiently than the 
dimer. These data suggest that assembly of 
two BLT2 protomers into a dimer results in 
reduced ability to signal. 
 
G protein-coupled receptors (GPCRs), the 
largest family of integral membrane proteins 
(1-3), participate in the regulation of most 
physiological functions and are the targets of 
30-50% of currently marketed drugs. In light 
of their biological and therapeutic importance, 
gaining detailed knowledge of their structural 
organization remains one of the most crucial 
task, but also, a great challenge facing modern 
biomedical research.  
Dimerization/oligomerization is a common 
phenomenon in the GPCR superfamily (4), but 
its role in the structure, function and signaling 
of these receptors has still to be clarified. It is 
unambiguously evidenced that class C GPCRs 
exist and function as stable dimers (5). 
However, whether or not class A GPCR 
dimerization is necessary for G protein 
activation is still a crucial biological question 
(6). Indeed, for rhodopsin-like receptors, a role 
for monomers and dimers in signal 
transduction is still a matter of intense debate 
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and investigation (7, 8). Although evidence of 
GPCR dimerization is accumulating even in 
native tissues (9), perfect functionality in terms 
of G protein activation has been reported so far 
for four different monomeric GPCRs. Indeed, 
monomers of rhodopsin, β2-adrenergic 
receptor (β2AR), neurotensin NTS1 receptor 
and opioid µ receptor (MOR), efficiently 
activate their cognate G proteins, i.e. the 
transducin Gt (10, 11), the stimulatory G 
protein Gs of adenylyl cyclase (AC) (12), the 
stimulatory G protein Gq of phospholipase C 
(PLC) (13), and the inhibitory G protein Gi of 
AC (14), respectively.  
Here, we investigated and compared the 
efficiency of isolated dimers and monomers of 
a prototypical GPCR to activate the purified 
Gi2 protein. As a model, we used the Gi-
coupled human leukotriene B4 (LTB4) BLT2 
receptor (15, 16), which plays critical roles in 
inflammation and immunological diseases (17, 
18). To produce sufficient amounts of pure and 
functional BLT2, isolate monomers from 
dimers and reconstitute receptor/G protein 
complexes, we have developed an original 
strategy. This approach is based first on the 
fusion of the receptor to an integrin fragment 
that allowed efficient overexpression in 
inclusion bodies (IBs) of the prokaryote 
Escherichia coli (E. coli), then on refolding 
and functional purification of the receptor, and 
finally on size exclusion chromatography 
(SEC) of the different species. Using the 
purified preparations of BLT2 monomers and 
dimers, we provide strong evidence that BLT2 
monomers activate the Gi2 protein more 
efficiently than dimers.   
 
EXPERIMENTAL PROCEDURES 
The construction, expression, and purification 
of the different GPCR fusions, as well as their 
thrombin cleavage and the subsequent 
purification of isolated GPCRs are described in 
the Supplemental Information section. 
Refolding of the BLT2 receptor. The 
leukotriene BLT2 GPCR, purified by 
immobilized-metal affinity chromatography 
(IMAC) in elution buffer (20 mM Tris-HCl pH 
8.00, 8 M urea, 0.2 % SDS, 150 mM NaCl, 
protease inhibitors (benzamidine (10 µg/ml), 
leupeptine (5 µg/ml), and 
phenylmethylsulfonylfluorid (PMSF; 10 
µg/ml), 100 mM imidazole), was dialyzed 
overnight at 20°C in dialysis buffer (25 mM 
Tris-HCl pH 8.00, 50 mM NaCl, 0.4% SDS) to 
eliminate urea and imidazole using Slide-A-
Lyser dialysis cassettes (Pierce, 10 KDa 
molecular weight cut-off). The quantity of 
BLT2 was determined by UV 
spectrophotometry using the Beer-Lambert law 
and calculation of molar extinction coefficients 
(19). Homogeneity of the preparation was 
checked by recording the scattering light and 
the fluorescence emission (20). We ensured 
that the concentration of the GPCR was 0.1-0.5 
mg per ml. Refolding of the BLT2 was first 
developed using a miniaturized protocol 
allowing comparison of many parameters such 
as pH, ionic strength, temperature, detergents, 
concentration of detergents, lipids, additives 
like cholesterol. To determine whether 
exchange of SDS with detergents (Anatrace) 
and/or lipids (Fluka) could produce active 
receptors from the denatured purified samples, 
systematic ligand binding competency of the 
refolded fraction was measured using [3H]-
LTB4 (22 Ci/mmol, PerkinElmer). Refolding 
was conducted at 20°C after binding of the 
6xHis tag of the GPCR to the Ni-NTA 
superflow resin (Qiagen). Briefly, 0.5 ml of 
Ni-NTA superflow slurry was loaded onto a 
Qiaprep spin column (Qiagen) that had been 
equilibrated twice with the dialysis buffer. The 
GPCR sample (0.1-0.5 mg per ml) was loaded 
onto the Ni-NTA resin by a 3-step 
centrifugation at very low speed (30 x g) for 2 
min. After this step, 75 to 100 µg of the 
receptor was bound to the resin. Optimized 
refolding was achieved by low speed 
centrifugation using 4 x 0.5 ml of detergent 
buffer (25 mM Tris-HCl pH 8.00, 50 mM 
NaCl, n-dodecyl phosphocholine (DPC) and 
hexadecyl-β-D-maltoside (HDM) (1:1 
DPC:HDM ratio), asolectin (1:15 
protein:detergent and 1:5 detergent:lipid mass 
ratios), 0.02% cholesteryl hemisuccinate 
(CHS)). Elution of the refolded GPCR was 
performed with 2 x 0.5 ml of elution buffer (25 
mM Tris-HCl pH 8.00, 50 mM NaCl, 
DPC/HDM/asolectin/CHS and 300 mM 
imidazole) using a final low-speed 
centrifugation step. The refolded GPCRs were 
kept on ice or at 4°C until use. Determination 
of the yield of the refolding step and 
quantification of the protein concentration 
were performed by UV spectrophotometry as 
described above (18).  
Ligand-affinity purification of the BLT2 
receptor. To isolate the active population 
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(corresponding to the fraction able to bind the 
ligand) of the BLT2 receptor, the IMAC-
purified GPCR was dialyzed overnight at 20°C 
in 25 mM Tris-HCl pH 8.00, 50 mM NaCl, 
0.4% SDS containing 5 mg/mL asolectin 
before refolding. Refolding was typically 
carried out at a protein concentration of 0.1-0.5 
mg/ml. The unfolded protein was immobilized 
onto the Ni-NTA matrix as described above. 
The resin was then washed with 10 column 
volumes of a buffer of 12.5 mM Na-borate, 10 
mM NaCl, 10% glycerol, pH 9.0 containing 
DPC and HDM as the detergents (1:1 
DPC:HDM ratio), asolectin (1:15 
protein:detergent and 1:5 detergent:lipid mass 
ratios), and 0.02% CHS. Elution of the 
refolded protein was carried out with the same 
buffer containing 0.3 M imidazole. All 
subsequent steps were carried out at 4°C. The 
IMAC-purified and refolded receptor was 
dialyzed overnight in a buffer containing 12.5 
mM Na-borate pH 7.5, 10 mM NaCl, 
DPC/HDM/asolectin/CHS (see above for 
detergent and lipid concentrations). The 
unfolded aggregated fractions were removed 
through a gel filtration chromatographic step 
on a Sephacryl S200 HR column (1.5 x 100 
cm, GE Healthcare) using the same buffer. 
Finally, the active receptor was ligand-affinity 
purified on a 5bα-bound affinity column. The 
5bα antagonist molecule was immobilized 
through its free carboxylate moiety on an Affi-
Gel 102 (Bio-Rad) matrix (21). Immobilization 
was carried out as described by the 
manufacturer. The refolded BLT2 receptor was 
recirculated (flow-rate 0.5 mL/min) on the 
matrix for at least 12 hours in the above buffer, 
and then washed with the same buffer. The 
receptor was then eluted with the buffer 
containing 0.1 mM 5bα. The antagonist was 
removed from the eluted protein by dialysis for 
36 hours against buffer containing 12.5 mM 
Na-borate pH 7.5, 10 mM NaCl and 
DPC/HDM/asolectin/CHS. Following this 
step, the BLT2 concentration was in the 10-6-
10-7 M range. When necessary, the protein 
preparation was concentrated by ultrafiltration 
(centricon 30 device, Amicon) and 
subsequently dialyzed to reequilibrate the 
detergent concentration. 
Radiolabeled ligand binding assays. Binding 
of a radiolabeled ligand to the purified soluble 
BLT2 was done by equilibrium dialysis at 
18°C for 24 hours. Dialysis cassettes from 
Dianorm (The Nest Group, Inc.) with two 250-
µl cavities separated by high-permeability 10 
KDa molecular weight cut-off dialysis 
membranes were used. Binding buffer 
containing 12.5 mM Na-borate pH 7.5, 10 mM 
NaCl and DPC/HDM/asolectin/CHS was used 
in all dialysis experiments, with protein 
concentrations in the 10-7 M range. 200 µl of 
receptor and 200 µl of tritiated ligand were put 
in each cavity of the cassettes at the beginning 
of the procedure. The cassettes were held in a 
multiequilibrium apparatus (Dianorm) in order 
to ensure constant stirring of the samples. To 
measure nonspecific binding, a series of 
control experiments was done in parallel in 
which an excess of unlabeled ligand was added 
together with the radiolabeled ligand on one 
side of the cassette. Another series was 
included in the experiment without the receptor 
at each concentration to control free diffusion 
of the radiolabeled ligand alone through the 
dialysis membrane. [3H]-LTB4 was used as the 
radioligand. Affinity of the [3H]-LTB4 was 
directly determined in saturation experiments, 
with concentrations ranging from 750 nM to 
30 nM. Unlabeled LTB4 was used in the 
control experiment at 100 µM to measure 
nonspecific binding. At the end of the 
equilibrium dialysis, samples were recovered 
from each cavity of each cassette and the 
radioactivity determined by scintillation 
counting. The ligand binding data were 
analysed by nonlinear least-squares regression 
using the computer program Ligand (Elsevier-
Biosoft).  
Fluorescence-based ligand binding assays. 
Saturation and competition ligand binding 
experiments with purified BLT2 monomers 
and dimers (see below) were performed using 
fluorescence anisotropy with LTB4 labeled 
with AlexaFluor-568 (LTB4-568) following the 
method described by Sabirsh et al. (22). 
Briefly, LTB4-568 was produced using LTB4-
aminopropylamide (LTB4-APA; Biomol 
International Inc.) and amine-reactive 
succinimidyl ester of AlexaFluor-568 
(Invitrogen, Molecular Probes products). 
Binding buffer containing 12.5 mM Na-borate 
pH 7.5, 10 mM NaCl and 
DPC/HDM/asolectin/CHS was used for these 
experiments with BLT2 monomer or dimer 
concentrations at 10-7 M. Saturation assays 
were performed using up to 0.9 µM fluorescent 
LTB4 with or without 100 µM LTB4. For 
competition assays, fluorescence experiments 
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were carried out at a constant LTB4-568 
concentration of 350 nM. The different ligands 
were added at increasing concentrations and 
binding lasted for 30 minutes at 15°C. 
Fluorescence anisotropy associated with 
BLT2-bound LTB4-568 was measured using a 
Cary Eclipse fluorometer equipped with an 
anisotropy device. Data were recorded as 
millianisotropy units as a function of 
competing ligand concentration and converted 
as  of maximum. 
G protein coupling assays. Two different 
types of experiments were carried out to 
demonstrate functional coupling of purified 
receptor monomers and dimers to the Gi 
protein.  
First, a nucleotide exchange assay using the 
purified Gαi2 subunit was carried out as 
described by Hamm and colleagues (23). Gαi2 
was prepared as already published (24). For 
measuring systematic activation of the G 
protein, the basal rate of GTPγS binding was 
determined by monitoring the relative increase 
in the intrinsic fluorescence (λexc=300 nm, 
λem=345 nm) of Gαi2 (200 nM of purified 
Gαi2) in the presence of BLT2 (20 nM, the 
final receptor to G protein molar ratio is 1:10) 
in buffer containing 10 mM MOPS (pH 7.2), 
130 mM NaCl and 2 mM MgCl2 for 40 min at 
15 °C after the addition of 10 µM GTPγS. The 
detergent/lipid mix 
(DPC/HDM/asolectin/CHS) was kept constant 
for preserving receptor structure. Similarly, the 
receptor-catalyzed rate was measured under 
the same conditions in the presence of 50 µM 
LTB4. The data were normalized to the 
baseline (buffer contribution, 0%) and the 
fluorescence maximum obtained with BLT1 
(20 nM in the presence of 1 µM LTB4, 100%). 
A negative control experiment was also carried 
out under the same conditions with the 
recombinant 5-HT4(a) receptor. For kinetic 
studies, purified Gβ1γ2 subunits (500 nM) were 
added in the mixture. The β1γ2 subunits of the 
G protein were prepared as described 
previously (24). Effects on fluorescence 
changes were also recorded under the same 
conditions in the presence of 20 µM of the 
BLT2 antagonist LY255283. 
Second, we directly measured the amount of 
GTP binding in a more classical way using  
radiolabeled [35S]GTPγS. Incorporation of the 
non-hydrolyzable [35S]GTPγS (1250 Ci/mmol, 
PerkinElmer) was done in the buffer used for 
monitoring the intrinsic fluorescence of Gαi2, 
in the presence of 10 mM MgCl2 instead of 2 
mM. [35S]GTPγS was used at ~2.5 nM 
(~1200000 dpm per reaction). The BLT2 
(monomer, dimer or mixed populations) and 
the Gαi2 were added at a 1:1 molar ratio (20 
nM each), with an excess of Gβ1γ2 subunits 
(500 nM). The detergent/lipid mix 
(DPC/HDM/asolectin/CHS) was kept constant 
during the incubation which was done at 25°C 
for 10 min. For measuring the agonist-induced 
receptor-dependent activity of the Gαi2, 1 µM 
of LTB4 was added in the mixture. Nonspecific 
binding was determined in the presence of 100 
µM GTPγS. The reaction was stopped by 
putting the tubes in a ice-cold bath. Specific 
[35S]GTPγS binding (separation of free and 
bound radiolabeled GTP analogue) was then 
quantified by equilibrium dialysis using 
dialysis cassettes and membranes equivalent to 
those described above for radiolabeled [3H]-
LTB4 binding studies. To ensure complete 
equilibration of labeled [35S]GTPγS and cold 
GTPγS, the dialysis lasted for 4 hours and 30 
min. Samples were then recovered from each 
cavity of each cassette and radioactivity was 
determined by liquid scintillation counting. 
Separation of oligomeric states of BLT2 by 
size exclusion chromatography. SEC 
experiments were carried out on a Superose 6 
column (16x70 mm, GE Heathcare). The 
column was first equilibrated with the 12.5 
mM Na-borate pH 7.5, 10 mM NaCl, 
DPC/HDM/asolectin/CHS buffer. The ligand 
affinity-purified BLT2 sample at a 10-6-10-7 M 
range concentration (1 mL in buffer 12.5 mM 
Na-borate pH 7.5, 10 mM NaCl, 
DPC/HDM/asolectin/CHS) was then loaded on 
the column and gel filtration was carried out 
with the equilibration buffer at a 0.2 mL/min 
flow rate. 0.3 mL fractions were collected. The 
oligomeric state of the receptor in the different 
fractions was then assessed using a chemical 
cross-linking approach with 
dithiobis(succinimidylpropionate) (dTSP), as 
previously described (25). Briefly, the different 
receptor fractions were submitted to cross-
linking at room temperature, after addition of 
dTSP (125 mM stock solution in N,N-
dimethylformamide) to a final protein-to-cross-
linker molar ratio of 1:10. The optimal cross-
linking time value was inferred from a time 
course analysis of the cross-linked species. The 
reaction was stopped by addition of glycine to 
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a final concentration of 50 mM. The cross-
linked species were then submitted to SDS-
PAGE analysis under non-reducing conditions 
and the intensity of the electrophoretic bands 
determined by densitometry (public domain 
NIH Image software). The BLT2 monomer 
and dimer receptor fractions were used to 
catalyze exchange of GDP for GTPγS on Gαi2 
as described above in the presence of Gβ1γ2 at 
1 µM and increasing concentrations in Gαi2. 
The BLT2 receptor concentration was kept 
constant at 20 nM in the assays. The duration 
of the reaction was 15 min in all cases. GTPγS 
binding in the absence of LTB4 was subtracted 
from that in the presence of 1 µM LTB4 and 
the resulting data were analyzed by using a 
one-site binding equation (Prism software, 
GraphPad) to assess the Km values for Gαi2 
saturation of receptor-catalyzed GDP/GTPγS 
exchange. Data were normalized both to the 
fluorescence maximum observed for saturating 
G protein concentrations (in the 10 µM range) 
and to BLT2 receptor concentration. 
Fluorescence resonance energy transfer 
(FRET) studies. For the FRET experiments, 
the BLT2 receptor was labeled at the N- or C-
terminus with AlexaFluor-488 or AlexaFluor-
568 (Invitrogen, Molecular Probes products) as 
a donor and acceptor of fluorescence, 
respectively. N-terminal labeling was carried 
out as described for the BLT1 receptor (26), 
using a dye/protein molar ratio 10:1. Under the 
conditions used, a labeling of ~0.9 was 
achieved, as assessed by measuring the 
absorbance of the protein at 276 nm and that of 
the dye at its absorbance maximum. C-terminal 
labeling of the receptor was carried out by 
using the transglutaminase (TGase) approach 
described by Jäger et al. (27). For this, the 
TGase tag Pro-Lys-Pro-Gln-Gln-Phe-Met was 
appended at the C-terminal end of the protein 
(the construction of the expression plasmid is 
described in Supplemental Information 
section). The fusion protein α5I-BLT2 was 
thus purified as described for the wild-type 
receptor, dialyzed as indicated above and 
labeling carried out as described by Jäger et al. 
(27). Briefly, the protein (10 µM) in a 20 mM 
Tris-HCl pH 8.0, 150 mM NaCl buffer was 
incubated with 1 mM Alexa dyes (dye/protein 
molar ratio 100:1) and 0.5 units of TGase 
(Sigma) for 24 hours at 25°C in the dark. The 
unreacted dye was then removed by gel 
filtration. Labeling yields of 85-90% were 
achieved under these conditions, as assessed 
by the absorbance of the protein at 276 nm and 
that of the dye at its maximum. The fusion 
partner was then cleaved and removed as 
described for the wild-type receptor. For dimer 
assembly, receptor labeled either with the 
fluorophore donor or acceptor were mixed in 
equivalent amounts (molar ratio 1:1) before 
refolding. Then, refolding and purification was 
carried out as described above for the 
unlabeled BLT2. Fluorescence emission 
spectra were recorded at 25°C between 490 
and 700 nm on a Cary Eclipse 
spectrofluorimeter with an excitation at 480 
nm or 570 nm. Buffer contributions were 
systematically subtracted. The FRET ratio 
corresponded to the ratio of the acceptor 
emitted fluorescence at 603 nm following 
excitation at two different wavelengths, 480 
and 570 nm (28). 
Statistical analysis. All data are reported as 
group means ± SEM. Statistical significance of 
the differences between independent groups 
were assessed by paired t-test. 
 
RESULTS 
Identification of new fusion partners for 
efficient GPCR overexpression in E. coli IBs. 
In order to produce recombinant GPCRs in 
sufficient amounts to reconstitute, in vitro, 
receptor/G protein complexes, we used an 
approach that had been initially described for 
the olfactory OR5 receptor and which is based 
on the accumulation of the receptor target in E. 
coli IBs as a fusion protein and on subsequent 
in vitro refolding (29, 30). Although the 
concept of this approach has been set up for 
overexpression and functional refolding of the 
leukotriene BLT1 and the serotonin 5HT4(a) 
receptors (31, 32), a generic and reliable 
method for GPCR accumulation in IBs has not 
been reported so far (33). To this end, we 
explored an alternative based on the 
identification of novel original fusion partners 
able to produce full-length receptors in high 
amounts, and that would be applicable to most 
GPCRs. We thus defined three criteria: 1) the 
fusion partner has to be targeted to IBs and 
highly accumulated when expressed as an 
isolated protein; 2) based on statistical 
predictions which correlate targeting of the 
recombinant protein to IBs with its primary 
sequence and physico-chemical properties 
(34), both the partner and the fusion have to be 
classified as insoluble; 3) the length of the 
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fusion partner was limited to a maximum of 
600 residues. We thus selected a non-specific 
PLC of Bacillus cereus (35), the glutamine 
phosphoribosyl pyrophosphatase 
amidotransferase (PurF) of E. coli (36), and a 
fragment of the extracellular β-propeller 
domain of the human α5 integrin (α5I) (37). 
According to statistical predictions (34), the 
two most important parameters controlling 
inclusion body formation (or insolubility) are 
charge average and fraction of β-turn-forming 
residues. As indicated in Table 1, the PLC, the 
PurF and the α5I all possess a higher β-turn-
forming residue fraction than the usual partner 
Glutathione-S-transferase (GST). Moreover, 
with respect to charge, both PurF and α5I 
contain much higher proportions of charged 
residues than PLC or GST. These observations 
suggested that PurF and α5I proteins may 
constitute the best potential candidates.  
GPCR production and purification. 
Both α5I and PurF appeared as very efficient 
partners for accumulating GPCRs in IBs, based 
on the data with the human arginine-
vasopressin (AVP) V2 receptor used as a 
reference (see Supplemental Figure S1). In 
addition, the α5I allowed efficient 
overexpression in E. coli IBs and purification 
of several other class A GPCRs (rhodopsin-
like) varying with respect to their length (from 
337 to 472 amino acids), their physico-
chemical properties, their G protein coupling 
selectivity and the nature of their specific 
ligand (Figure 1). Although with different 
efficiencies, high amounts of the 
catecholamine β3AR, the hormone AVP V2 
receptor and oxytocin (OT) receptor (OTR)), 
the chemokine CCR5 and CXCR4 receptors or 
chemokine-like ChemR23 receptor, the 
cannabinoid CB1 receptor and the bioactive 
lipid leukotriene BLT2, CysLT1 and CysLT2 
receptors, were overexpressed. The V2, β3AR, 
ChemR23, BLT2, CysLT1, CysLT2, and CB1 
receptors were produced and purified as simple 
α5I fusions (Figure 1A). The leukotriene BLT1 
and the AVP V1b receptors were also 
accumulated and purified using this strategy 
(data not shown). In addition, the OTR, 
CXCR4, and CCR5 were only produced as 
complex α5I-V2 fusions (Figure 1B). Apparent 
molecular weight of each fusion was 
compatible with the corresponding calculated 
masses (70-75 kDa for the α5I-GPCR fusions, 
around 120 kDa for the α5I-V2-GPCR 
fusions). Moreover, the integrity of the 
different fusions was confirmed both by N-
terminal Edman sequencing and 
chemiluminescence detection of the GPCR C-
terminal 6xHIS tag (data not shown).  
For each fusion, the α5I partner was efficiently 
removed by thrombin cleavage and the isolated 
GPCRs purified using a second IMAC. 
Complex fusions (e.g. α5I-V2-OTR) required 
an additional gel filtration step before the 
IMAC purification for eliminating uncleaved 
proteins. As illustrated in Supplemental Figure 
S2, representative purified OTR, ChemR23, 
V2 and β3AR, appeared as two major bands, 
corresponding to a monomer at 35-40 kDa and 
to a dimer at around 75 kDa. Identity of each 
receptor monomer and dimer was confirmed 
by direct N-terminal Edman sequencing. The 
quantity of each purified receptor was 
calculated as indicated in Experimental 
procedures: it varied from 0.2-0.5 mg (OTR 
for instance) to 2-3 mg (e.g. the V2 or the 
BLT2) from 100 ml of bacterial cell culture 
(equivalent to 0.6 g wet cells). 
In vitro refolding, functional purification and 
binding properties of the ligand-competent 
BLT2 receptor. As stated above, the BLT2 
receptor was efficiently accumulated in E. coli 
IBs and purified as a denatured protein in large 
quantities. Refolding conditions were 
subsequently explored as described for the 
BLT1 receptor (31). The BLT2 receptor was 
refolded to its native state in well-defined 
detergent/lipid mixed micelles 
(DPC/HDM/asolectin/CHS). Under such 
conditions, the ligand-competent fraction 
represented around 4% of the total receptor 
preparation, as determined by [3H]-LTB4 
binding. The ligand-competent fraction of the 
BLT2 was then purified through a ligand-
immobilized affinity chromatography 
procedure using the LTB4 antagonist 5bα (20). 
Homogeneity of the affinity-purified BLT2 
was demonstrated by binding assays with [3H]-
LTB4 (Figure 2). The calculated linear 
Scatchard plot revealed the presence of a 
single population of binding sites and a 
stoichiometric ratio of 1:1 ligand molecule per 
receptor was calculated (Bmax = 1.06 ± 0.02; 
n=3). It has been previously shown with native 
BLT2 that a receptor molecule binds a single 
ligand (15). The occurrence of a 1:1 
ligand:BLT2 molar ratio with our recombinant 
pure receptor therefore implies that all 
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receptors in the preparation are in a ligand-
competent state.  
It is to be noted that, despite this homogeneity, 
the [3H]-LTB4 affinity for the BLT2 (Kd = 232 
± 29 nM (n=3)) is significantly lower than that 
described for the receptor expressed in 
mammalian HEK293 cells, 22.7 nM (15). This 
could be due to the lack of interaction with 
stabilizing membrane lipids or protein partners 
such as G proteins, as it was demonstrated for 
the other LTB4 receptor BLT1 (31) or the 
serotonin 5HT4(a) receptor (32). Because BLT2 
was demonstrated to couple to Gi protein (15-
17), we reconstituted the affinity-purified 
receptor with the purified Gi2 subunit. A 
significant increase in the affinity of BLT2 for 
the LTB4 agonist was observed in the presence 
of the Gi2 protein (Figure 2,); in that case, the 
measured Kd was 49 ± 5 nM (n=3). This value 
was much closer to that for BLT2 expressed in 
HEK293 cells, indicating that agonist high-
affinity binding state of the refolded affinity-
purified BLT2 is dependent on the presence of 
the G protein.  
G protein coupling properties of the affinity-
purifed BLT2 receptor.  
Functionality of the affinity-purified BLT2 
was assessed by monitoring the relative 
increase in the intrinsic fluorescence of Gi2 
after addition of GTPγS to the purified G 
protein subunit reconstituted with the BLT2 in 
the absence or presence of LTB4. A significant 
BLT2-catalyzed GTPγS binding occurred upon 
binding of the LTB4 (Figure 3A). Moreover, 
the amount of GTPγS bound to Gi2  was found 
similar to that induced by the LTB4 stimulation 
of BLT1 receptor, as previously described 
(24). By contrast, a purified 5HT4(a), which is 
not naturally coupled to Gi, was unable to 
stimulate GTPγS binding (32). The kinetics of 
the G protein Gi2-BLT2 receptor coupling were 
recorded in the presence of Gβ1γ2 subunits 
(Figure 3B) or in their absence. As illustrated, 
the LTB4-stimulated GTPγS incorporation was 
fast and saturated within 15 min (profile 2). It 
remained stable for longer periods of 
interaction. This result could be mimicked in 
the absence of the Gβγ subunits, but the rate of 
increase was slower and saturated within 40 
min instead of 15 min (data not shown). As 
expected, the BLT2 specific antagonist 
LY255283 was unable to stimulate GTPγS 
binding (profile 3), and the intrinsic 
fluorescence signal was equivalent to that of 
the basal condition (profile 1). Interestingly, 
the time-course and maximal incorporation of 
GTPγS measured in the presence of BLT2/G 
protein was equivalent to that recorded with 
the BLT1 receptor positive control (profile 4). 
These results confirmed that coupling of the 
affinity-purified BLT2 receptor to the G 
protein was functional as well in terms of 
kinetics, although Gβγ were necessary for 
rapid GTPγS binding. 
Oligomeric state of the affinity-purified BLT2 
receptor. We then analyzed the oligomeric 
state of the ligand affinity-purified BLT2 
receptor using a SEC approach. As shown in 
Fig. 4A, a main peak was observed that was 
centered at about 70 mL. No peak was 
observed in the dead volume of the column 
indicating the absence of high molecular 
species that could correspond to aggregated 
receptor. As clearly shown in Fig.4A, the main 
peak displayed a well-defined shoulder at ca. 
65 mL indicating the occurrence of different 
species in the eluted fractions. 
To assess the oligomeric state of the different 
receptor populations in this elution peak, we 
carried out a series of chemical cross-linking 
experiments. The different fractions making 
the elution peak were pooled in three main 
fractions, labeled 1, 2 and 3 as a function of 
their elution volume. The proteins in these 
fractions were then submitted to chemical 
cross-linking using dTSP as a disulfide 
reagent, as previously described with the BLT1 
receptor (31). The extent of cross-linking was 
finally assessed by SDS-PAGE under non-
reducing conditions (see inset to Fig. 4A). A 
major band at ~66 kDa was observed for the 
first protein fractions eluted from the SEC 
column (fraction 1). This mass value is 
compatible with that of the homodimeric 
BLT2. However, in this case, a minor band 
with an electrophoretic mobility compatible 
with that of the receptor monomer was still 
observed that corresponded to less than 5% of 
the total protein, as assessed by densitometric 
analysis of the SDS-PAGE gel (not shown). 
The occurrence of this band after cross-linking 
could arise either from an incomplete chemical 
cross-linking or from the presence of a minor 
fraction of monomeric receptor. In contrast, the 
last eluting proteins (fraction 3) strictly 
correspond to protein species with an 
electrophoretic mobility at ~35 kDa 
compatible with that of the monomeric BLT2. 
This indicates that the receptor purified 
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following ligand-immobilized chromatography 
essentially corresponds to a mixture of 
monomeric and dimeric species that can be 
separated using SEC. As expected, the protein 
fractions at intermediate elution volumes, i.e. 
fraction 2, correspond to a mixture of 
monomer and dimer, as assessed by chemical 
cross-linking. 
We finally determined the topological features 
of the BLT2 dimer, i.e. whether the two 
protomers in the dimeric assembly are in a 
parallel or antiparallel orientation. For this, we 
devised a FRET-based approach that consisted 
in labeling either the N-terminus of the C-
terminus of the receptor with a fluorescence 
donor or acceptor and then measuring the 
transfer efficiency between these two probes to 
assess proximity (see Experimental procedures 
section). N-terminal labeling was carried out as 
described for BLT1 (26). To specifically label 
the receptor C-terminus, we introduced a 
transglutaminase recognition sequence that 
allows enzymatic modification of a reactive 
glutamine and incorporation of a fluorophore 
(27). The receptors labeled with the donor 
(AlexaFluor-488) and acceptor (AlexaFluor-
568) probes were mixed in equivalent amounts 
before refolding and then were refolded and 
the dimers purified as described above. As 
expected, under such conditions, essentially 
equivalent amounts of donor- and acceptor-
labeled protein were found in the dimeric 
fraction (fraction 1 as above), based on the UV 
absorption features of the proteins in this 
fraction (see Experimental procedures). Since 
labeling does not affect the dimerization 
properties of BLT2 (similar SEC profiles were 
obtained for both the labeled and unlabeled 
proteins; not shown), one can expect the final 
dimeric fraction to be composed of a mixture 
of dimers where both protomers are labeled 
with the donor or with the acceptor molecule, 
and dimers where each of the protomers is 
labeled either with the donor or with the 
acceptor. Moreover, the distance between the 
extreme N- and C-termini of the BLT2 is 
expected to be significantly larger than the R0 
value (~60 Å) of the fluorophore pair used in 
the experiments, based on the different GPCR 
crystal structures obtained so far and 
biophysical data published for the 
fluorescently-labeled β2AR (38, 39). 
Consequently, FRET was expected to arise 
only from the latter species. As shown in 
Figure 4B, a significant FRET signal was 
observed when protomers were labeled either 
both at the N-terminus or both at the C-
terminus. This strongly suggested that the N-
terminal regions are in proximity in the 
dimeric assembly, as well as both C-termini. 
This is likely to be a specific effect of receptor 
dimerization since no signal was observed with 
the monomeric fractions (fraction 3 as above), 
ruling out possible collisional effects. In 
contrast, no signal was observed when one of 
the protomers was labeled at its N-terminus 
and the other at the C-terminus. All these data 
indicate that the two protomers in most, if not 
all dimers, are likely in a parallel orientation. 
Pharmacology of the BLT2 monomer and 
dimer. To assess that both monomeric and 
dimeric BLT2 populations were functional, we 
first measured the ligand-binding properties of 
the different fractions obtained after SEC. A 
similar Kd value for [3H]-LTB4 was measured 
for both species, i.e. 255.8 ± 35.2 nM (n=3) 
and 253.3 ± 38.7 nM (n=3) for the monomeric 
and dimeric fractions, respectively. This is in 
agreement with the Kd calculated for the 
refolded affinity-purified BLT2 (see above). 
Moreover, the stoichiometric ratio of ~1 
obtained for the receptor dimer indicates that 
both protomers in the dimeric assembly are 
able to bind the LTB4 agonist. We then 
checked whether the receptor monomer and 
dimer displayed different pharmacological 
profiles. For this, we carried out a series of 
saturation and competition experiments using 
fluorescence anisotropy and the LTB4 
derivative LTB4-568 as a fluorescent probe. 
Both this probe and the fluorescence 
anisotropy approach for monitoring ligand 
binding to the LTB4 receptors have been 
described previously (22). We first determined, 
by saturation fluorescence anisotropy binding 
assays, that affinity of the LTB4-568 for BLT2 
monomers and dimers was in the same range 
than that defined with [3H]-LTB4 for dimers 
and monomers, respectively. Indeed, LTB4-
568 affinity was calculated to be Kd = 310 
(n=2) for monomers and 297 nM (n=2) for 
dimers. We then assessed the pharmacological 
profile of the monomer and dimer in 
competition assays using LTB4-568 as the 
fluorescent tracer. As shown in Figure 5, the 
two BLT2 populations displayed very similar 
pharmacological profiles, i.e. they both bound 
the LTB4 and 12-HHT agonists as well as the 
BLT2-specific LY255283 antagonist. In 
contrast, the BLT1-specific U75302 agonist 
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did not significantly displaced LTB4-568 
binding, considering either the monomer or the 
dimer. Such a pharmacological profile is fully 
compatible with what has been reported for the 
BLT2 receptor expressed in neutrophils or 
transfected cell membrane fractions [15-18, 22, 
40]. Moreover, as shown in Table 2, similar 
IC50 values were obtained for all the ligands 
whether the monomer or the dimer are 
considered, indicating that dimerization of 
BLT2 has not a significant impact in its ligand 
binding properties. 
Monomer- and dimer-catalyzed G protein 
activation.  
We subsequently analyzed whether the BLT2 
monomer and dimer could efficiently activate 
the purified Gαi2β1γ2 protein. Using the 
fluorescence-based assay, we first assessed 
LTB4-catalyzed GTPγS incorporation to the Gi2 
protein with the BLT2 monomers and dimers 
in the presence of increasing concentrations of 
the agonist. As shown in Figure 6A, both 
fractions were able to trigger Gi2 activation. 
Half-saturation of LTB4-catalyzed GTPγS 
binding was reached at comparable agonist 
concentrations with monomers and dimers. 
We then analyzed the kinetic aspects of G 
protein activation triggered by the BLT2 
monomer and dimer still using the 
fluorescence-based assay. Interestingly, when 
normalized to the total number of LTB4 
binding sites, the reaction was approximately 
two times faster using the monomer compared 
to what was observed with the dimer (Fig. 6B, 
t1/2 = 3.6 min and 7.5 min for the monomer 
and the dimer, respectively). This suggests that 
the monomeric state of the receptor would 
represent the most active form of BLT2. To 
further investigate this observation on an 
experimental basis, we analyzed Gi2 saturation 
of BLT2-catalyzed GDP/GTPγS exchange 
with the two protein fractions, i.e. the 
monomeric and dimeric ones. As shown in 
Figure 6C, the BLT2 monomer in the presence 
of saturating LTB4 concentrations was 
completely able to trigger GDP/GTPγS 
exchange at the level of the Gi2 subunit with a 
Km value of 44.6 ± 7.6 nM (n=3). This clearly 
indicated that the receptor monomer is fully 
competent in terms of G protein activation. 
Interestingly, when the experiment was carried 
out with the protein fraction in which the 
receptor dimer was the major species, the 
calculated apparent Km value was significantly 
different by around 2 fold (82.0 ± 7.3 nM 
(n=3)). This suggests that for an equivalent 
number of bound agonists, the BLT2 dimer is 
less efficient than the monomer in terms of G 
protein activation.  
We finally confirmed the signaling reduced 
ability of the BLT2 dimer by directly 
measuring the receptor-dependent GTP 
binding activity of the Gi protein using  
radiolabeled [35S]GTPγS. To demonstrate that 
the receptors (monomers and dimers) are fully 
capable of G protein activation, each 
population of BLT2 and the Gi2 were added at 
a 1:1 molar ratio. As shown in Figure 6D, 
interestingly, the amount of specifically-bound 
[35S]GTPγS to the Gi2 following ligand 
stimulation of BLT2 monomer was 
significantly higher than that obtained with the 
BLT2 dimer (545766 ± 29740 dpm (n=4) 
versus 428547 ± 34200 dpm (n=4), p<0.05). 
For comparison, the incorporation of the 
radiolabeled nucleotide in the absence of 
ligand-receptor complexes (basal activity of 
the Gi2 protein) was much lower (131991 ± 
16430 dpm (n=6)). The one measured in the 
presence of the mixed population  (BLT2 
receptor before SEC separation) was 
intermediate (501026 ± 61580 dpm (n=4)). 
 
DISCUSSION 
We analyzed and compared here the capacity 
of GPCR dimers and monomers to activate 
their cognate G protein using the purified 
BLT2 receptor as a model. We showed that 
BLT2 monomer catalyzes GTPγS binding at 
the level of the Gi2 protein with higher affinity 
than the corresponding homodimer and with 
faster kinetics. We confirmed this result by 
directly measuring specific [35S]GTPγS 
incorporation to Gi2 in presence of either the 
BLT2 monomer or dimer with a saturating 
concentration of the LTB4 agonist. These 
results strongly suggest that for an equivalent 
number of ligand-occupied binding sites, 
BLT2 monomers activate Gi2 protein more 
efficiently than dimers.  
Our data indicate that the minimal BLT2 unit 
for Gi2 activation is the monomer and are in 
agreement with accumulating evidence 
showing that monomeric GPCRs are 
functional. Indeed, several studies 
demonstrated that monomeric rhodopsin is 
capable of full coupling to transducin Gt (11, 
41, 42). The NTS1 neurotensin receptor 
monomer was also shown to activate the Gq 
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protein better than its corresponding 
homodimer, although activation of Gq by 
monomeric and dimeric receptors has not been 
evaluated in the same conditions (13). Finally, 
the β2AR and the MOR were reconstituted 
into high-density lipoprotein particles at one 
receptor per particle and were shown to 
efficiently activate their selective G protein Gs 
and Gi, respectively (12, 14). Our data with 
BLT2 confirm that like Gt, Gq and Gs, Gi2 can 
be activated by a GPCR monomer, indicating 
that this is likely to be a common feature for all 
G protein subtypes. It is thus clear that 
although accumulating data reinforce the idea 
that GPCRs oligomerize in heterologous 
expression systems and in native cells (4, 9), 
the receptor monomer has per se all molecular 
determinants necessary for G protein 
activation. 
Since the BLT2 monomer appears as the 
minimal unit for G protein activation (at least 
in detergent/lipid mixed micelles), this raises 
the question of what mechanism is responsible 
for the reduced capacity of receptor dimers to 
activate G proteins. Different interpretations 
have been proposed so far.  
First, Bayburt et al. (41) have suggested that a 
lower efficiency of rhodopsin dimers to 
activate transducin could be the consequence 
of rhodopsin reconstitution into lipid nanodiscs 
that would result in a random orientation of the 
protomers in the dimer with two equal 
populations, parallel and anti-parallel, the latter 
being unable to activate transducin. In 
addition, Banerjee et al. have indeed 
demonstrated the occurrence of anti-parallel 
GPCR dimers incorporated in nanoscale 
apolipoprotein-bound bilayers using electron 
microscopy of nanogold-labeled rhodopsin 
(43). However, this is not the case here for 
BLT2 since we directly demonstrated using an 
original FRET-based approach that the 
receptor dimer is essentially composed of a 
single population with both protomers in a 
parallel orientation. In this context, our 
observation means that, although established in 
a detergent environment far from that of a 
native membrane, protein:protein contacts in 
the BLT2 dimeric entity are of sufficient 
specificity and lead to correctly folded and 
assembled dimers.  
Second, as proposed for the NTS1 receptor 
(13), steric hindrance between the two G 
protein binding sites in the dimer would be 
responsible for the reduced efficacy of the 
BLT2 dimer to activate Gi2. Such a model has 
also been proposed for rhodopsin for which 
steric constraints could prohibit interaction 
with more than one transducin at a time and 
explain why a rhodopsin dimer is less efficient 
than the monomer for transducin activation 
(41). Steric hindrance effects that would lead 
to G protein competition may also explain why 
activation by BLT2 dimers is less efficient. 
Although we have not so far any direct 
evidence for the stoichiometric features of the 
BLT2:Gi2 complex, this would favor, as 
suggested for rhodopsin, NTS1 or BLT1 
receptors (25), a complex where the BLT2 
dimer would efficiently interact with 
essentially a single Gi2 protein.  
A third possibility would be to consider a 
model recently proposed whereby dimerization 
could serve as a “desensitization” mechanism 
(44), rapidly suppressing G protein-mediated 
signaling when there are two many active 
receptors. In agreement with this hypothesis, 
dimerization could constitute a way to 
modulate G protein-mediated signaling. A 
reduced coupling efficiency of dimeric 
receptors to their cognate G protein, as 
observed in this work as well as for the 
neurotensin NTS1 or rhodopsin, would be 
consistent with this idea. Although, as 
proposed above, steric constraints could affect 
accessibility of one of the two protomers to the 
G protein and be responsible for this 
“desensitization” process, another possibility 
would be to consider a negative allostery 
mechanism between protomers through direct 
trans-conformational changes within the 
receptor dimer. In this case, agonist-induced 
conformational changes in one protomer, 
compatible with a complete activation of its 
cognate G protein, would trigger an inhibitory 
trans-conformational change of the second 
protomer. Such inhibitory cross-
conformational changes have been recently 
proposed to occur in a µ-opioid:α2A adrenergic 
receptor dimer (45). This study is consistent 
with asymmetric roles for GPCR subunits in 
receptor dimers. Examples of asymmetry for 
different class A GPCR families in terms of G 
protein activation have been reported (13, 24, 
41, 46). In addition, the asymmetric nature of 
GPCRs has also been elegantly analyzed with 
class C GPCRs. Very importantly, studies with 
metabotropic glutamate receptors mGlu1 and 
mGlu5 also support the conclusion that a G 
protein needs just one active protomer, and that 
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two protomers in the active conformation 
impede signaling (47, 48). 
It has to be strongly emphasized here that all 
the data presented on the differential activation 
of Gi2 protein by BLT2 monomers and dimers 
have been obtained because of the possibility 
to produce the receptor in high amounts in a 
functional state. This highlights the importance 
of the strategy we have developed that 
combines an original and efficient way to 
overexpress the receptor in E. coli IBs to the 
purification and refolding steps previously 
described (27, 29, 30). Indeed, improving the 
expression method allowed to obtain sufficient 
amounts of functional protein even with 
moderate refolding yields. Fusing the receptor 
to α5I led to high expression levels for all 
GPCRs tested, without any optimization of 
either the cell culture conditions or the 
extraction/purification procedures. This 
constitutes a significant improvement over 
what has been described to date with respect to 
expression levels in bacteria and therefore 
represents an important breakthrough for in 
vitro studies aimed at understanding the 
molecular bases of the function of class A 
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Fig. 1: Overexpression and purification of α5I-GPCR fusions. 
Samples were loaded onto 12% SDS-polyacrylamide gels and proteins stained with Coomassie Blue. 
To directly compare the purification yield, 10 µl of eluted fusions were put into each well. A) 
Schematic representation of α5I-GPCR fusions and comparison of the corresponding purified proteins: 
V2, β3AR, ChemR23, BLT2, Cys-LT1, Cys-LT2, or CB1 receptor (lanes 1 to 7). B) Schematic 
representation of α5I-V2-GPCR fusions and detection of the corresponding purified proteins. The 
entire α5I-V2 fusion was used as a new partner for expressing another GPCR: OTR, CXCR4, CCR5 
(lanes 1 to 3). 
Fig. 2: Binding of [3H]-LTB4 to the refolded affinity-purified BLT2 receptor.  
Three series of ligand-binding experiments were carried out by equilibrium dialysis in the absence 
(closed circles) or presence (open circles) of the purified Gαi2 protein (Inset: corresponding scatchard 
plots). The binding data are presented as a plot of the binding degree X as a function of the ligand 
concentration. X is defined by bound mole of LTB4 per mole of BLT2 (49). The experiments shown 
are representative of 3 independent trials, each performed in duplicate. Kd of [3H]-LTB4 was calculated 
as explained in Experimental Procedures. Mean values ± SEMs are given in Results. The statistics of 
the illustrated fits were as follow. The calculated Kd in the absence of G proteins was 217.8 ± 47.7 nM 
(22% error) with a binding ratio of 1.07 ± 0.08 (7.5% error). The calculated Kd in the presence of G 
proteins was 58.1 ± 18.9 nM (29% error) with a binding ratio of 1.09 ± 0.07 (6.5% error). 
Fig. 3: G protein coupling properties of the refolded affinity-purified BLT2 receptor. 
(A) BLT2-catalyzed GTPγS binding assessed by changes in the fluorescence of Gαi2. Experiments 
were carried out with the refolded BLT2 (20 nM) in the absence or presence of saturating 
concentrations of LTB4 (50 µM). For comparison, BLT1 and 5HT4(a) were also used at 20 nM and 
their ligands at 1 and 10 µM, respectively. Mean values ± SEMs are shown. Statistics are given: ***, 
p< 0.01. (B) Time course of the relative increase in the intrinsic fluorescence of Gαi2 upon addition of 
GTPγS. The fluorescence was monitored as described in Experimental Procedures in the presence of 
the purified BLT2 receptor in the absence of ligand (profile 1), in the presence of the LTB4 agonist 
(profile 2) or in the presence of the LY255283 antagonist (profile 3). The data were normalized to the 
changes induced by the purified BLT1 receptor in the presence of LTB4 (profile 4). The experiment 
illustrated here is representative of 3 independent assays. 
Fig. 4: Separation and characterization of monomeric and dimeric species of BLT2 receptor. 
 (A) Separation of monomeric and dimeric species of BLT2 by SEC. The affinity-purified BLT2 
preparation was loaded onto a Superose 6 column and the separation of the different species was 
carried out as described in the Experimental Procedures. The proteins eluted from the superose 6 
column were pooled in three fractions labeled 1, 2, and 3 as a function of their retention time, as 
indicated in the elution profile, and submitted to chemical cross-linking. Inset: SDS-PAGE analysis of 
the protein content in fractions 1, 2 and 3 after chemical cross-linking. (B) FRET ratio measured 
between alexaFluor-488- and alexaFluor-568-labeled BLT2 protomers. The species considered in each 
case are schematically represented below, where ( ) is the fluorescence donor and (   ) the acceptor. 
The upper position represents N-terminal labeling, the lower position corresponds to C-terminal 
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labeling. FRET ratios were calculated as indicated in Experimental Procedures (28). The experiments 
shown in the figure were repeated three times. Results are given as mean values ± SEM.` 
Fig. 5: Pharmacological profile of the BLT2 monomers and dimers. Fluorescence anisotropy-
monitored competition experiments were carried out using the fluorescent LTB4-568 and the BLT2 
monomer (A) or dimer (B) as described in Experimental Procedures (100 nM of monomers or dimers). 
Data are presented as fluorescence anisotropy (% of maximum, defined in the absence of displacing 
ligand) as a function of ligand concentration. Closed squares, LTB4: closed triangles, LY255283; 
closed circles, U75302; and open triangles, 12-HHT. The values are means from triplicates measured 
in an experiment representative of three independent assays, each done in triplicate. 
Fig. 6: Activation of the G protein Gαi2β1γ2 by monomeric and dimeric BLT2 receptors. (A) LTB4 
saturation of monomer (open circles) and dimer (closed circles) catalyzed GDP/GTP exchange. Data 
are presented as the percentage of maximal GTPγS binding as a function of LTB4 concentration. 
Results are given as mean values ± SEM calculated from three independent experiments. (B) time-
dependent activation of Gαi2 catalyzed by the LTB4-saturated form of the BLT2 monomer (closed 
circles) or dimer (open circles). Data are expressed as the percentage of maximal GTPγS binding as a 
function of time. The experiment shown is representative of three independent assays. In A and B, the 
BLT2 concentration was 20 nM, that of Gαi2 was 200  nM and those of Gβ1γ2 were 500 nM. (C) Gαi2 
saturation of GDP/GTPγS exchange triggered by the BLT2 monomers (closed circles; fraction 3 in 
Fig. 4) and dimers (open circles; fraction 1 in Fig. 4). The contribution of the basal exchange (around 
20% of the maximal receptor-catalyzed exchange) in the absence of agonist was systematically 
subtracted. The BLT2 concentration was 20 nM, those of Gβ1γ2 were in excess, 500 nM. Data are 
expressed as the percentage of maximal GTPγS binding normalized to BLT2 receptor concentration. 
The experiments shown in the figure were repeated three times. Results are given as mean values ± 
SEM. (D) [35S]-GTPγS binding to the Gαi2 in the presence of LTB4-stimulated BLT2 monomers and 
dimers. BLT2 receptor preparations and Gαi2 were added at an equimolar ratio (20 nM each) in the 
presence of 500 nM G protein β1γ2 subunits. Data are expressed as specific dpm incorporated to the 
Gαi2. Mean values ± SEMs are shown. Statistics are given: ***, p< 0.0001; *, p<0.05. These 





Table 1: Physico-chemical properties of the fusion partners. 
 
  Charge average   fraction of β-turn  length (amino  
      forming residues (%)  acid residues) 
__________________________________________________________________________________ 
 
GST   -2    18.7         224 
 
PLC   -2    22.7         258 
 
PurF   -14    21.4         504 
 
α5I   -19    31.6         285 
__________________________________________________________________________________ 
 
The physico-chemical parameters of each potential fusion partner were calculated according to 
Wilkinson and Harrison (34). The combination of a high fraction of both charged residues and β-turn 
forming residues is critical for targeting a recombinant protein to E. coli IBs. 
  
16 
Table 2: Ligand binding properties of the BLT2 monomer and dimer fractions. 
 
   LTB4  LY255283          U75302  12-HHT 
__________________________________________________________________________________ 
 
BLT2 monomer 404 ± 12 158 ± 13  n.m.     61 ± 3 
 




The data indicated in the table are IC50 (nM) values inferred from the fluorescence anisotropy 
competition binding experiments reported in Figure 5. These values are means ± SEM calculated from 
three distinct experiments carried out from two independent BLT2 monomer and dimer preparations. 
n.m., not measurable. 
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